asp3258

**ASP3258** is a potent and selective phosphodiesterase 4 (PDE4) inhibitor developed as an orally active anti-inflammatory agent, under evaluation mainly for the treatment of airway inflammatory conditions, such as asthma and chronic obstructive pulmonary disease (COPD). In animal models, ASP3258 effectively inhibits inflammatory cell infiltration, bronchoconstriction, and airway hyperresponsiveness with a potency comparable to that of roflumilast but exhibits lower emetic potential—a significant safety advantage for PDE4 inhibitors. Its metabolism is primarily via O-glucuronidation, leading to fecal-biliary excretion, and it displays rapid and extensive tissue distribution after oral administration[1][3][5].

Other names

3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl] propanoic acid